2026-04-24 20:30:08 UTC / 路透社
作者：帕德马纳班·安南坦
2026年4月24日 世界协调时晚上8:30 更新于1小时前
2025年11月6日，中国上海第八届中国国际进口博览会上，人们在强生公司展台的标识旁驻足。路透社/马克西姆·谢梅特/资料图片 获取授权许可，打开新标签页
4月24日（路透社）——强生公司（纽交所代码：JNJ.N）周五向路透社透露，将在特朗普政府旗下的TrumpRx网站上架四款旗下药物。
该公司表示，将通过TrumpRx平台及其直接面向消费者的网站JNJ Direct，提供糖尿病药物卡格列净二甲双胍（Invokamet）、卡格列净二甲双胍缓释片（Invokamet XR）、怡可安（Invokana），以及血液稀释剂拜瑞妥（Xarelto）。
订阅路透社健康周刊，及时了解最新医学突破与医疗趋势。点击此处注册。
这家医疗保健巨头于今年1月与特朗普政府自愿达成协议，降低美国民众的药品价格，在医疗补助计划（Medicaid）框架下扩大可负担处方药的可及性，并在TrumpRx平台上推广其产品，以此换取豁免该政府的关税。
广告 · 滚动继续阅读
包括辉瑞（纽交所代码：PFE.N）、诺和诺德（哥本哈根证交所代码：NOVOb.CO）、礼来（纽交所代码：LLY.N）和阿斯利康（伦敦证交所代码：AZN.L）在内的其他制药商，也已达成与TrumpRx相关的类似协议，或是签署了所谓的“最惠国定价”协议，旨在降低美国药品成本并鼓励本土生产。
TrumpRx旨在为持有有效处方的自费患者提供服务，包括无保险消费者以及保险不覆盖特定药品的人群。
强生此前承诺投入550亿美元用于研发与生产，其中包括在宾夕法尼亚州和北卡罗来纳州设立工厂。
帕德马纳班·安南坦在班加罗尔报道；维杰·基肖尔和马朱·塞缪尔编辑
我们的报道准则：汤森路透信任原则，打开新标签页
Johnson & Johnson to offer four prescription medicines on TrumpRx website
2026-04-24 20:30:08 UTC / Reuters
By Padmanabhan Ananthan
April 24, 2026 8:30 PM UTC Updated 1 hour ago
People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov/File Photo Purchase Licensing Rights, opens new tab
April 24 (Reuters) – Johnson & Johnson JNJ.N will start selling four of its medications on the Trump administration’s TrumpRx website, the company told Reuters on Friday.
The company said it would begin offering its diabetes drugs Invokamet, Invokamet XR and Invokana, as well as blood thinner Xarelto, through the TrumpRx platform and its direct‑to‑consumer website, JNJ Direct.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The healthcare conglomerate voluntarily reached an agreement with the Trump administration in January to reduce drug prices for Americans, expanding access to affordable prescriptions under Medicaid and marketing its products on the TrumpRx platform in exchange for an exemption from the administration’s tariffs.
Advertisement · Scroll to continue
Other drugmakers including Pfizer PFE.N, Novo Nordisk NOVOb.CO, Eli Lilly LLY.N and AstraZeneca AZN.L have entered into similar deals tied to TrumpRx or so‑called “most‑favoured‑nation” pricing aimed at lowering U.S. drug costs and encouraging domestic production.
TrumpRx is meant to serve cash‑paying patients with valid prescriptions, including uninsured consumers and those whose insurance does not cover a particular drug.
Johnson & Johnson previously pledged $55 billion in research and production, including facilities in Pennsylvania and North Carolina.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore and Maju Samuel
Our Standards: The Thomson Reuters Trust Principles., opens new tab
发表回复